

**Dr. Sally Burtles**  
**Joint Research Management Office**  
Queen Mary Innovation Centre  
5 Walden Street  
London  
E1 2EF

## Amendment Acknowledgement

30 June 2017

Dr Dan Hart  
Pathology & Pharmacy Building  
80 Newark Street  
London  
SE1 2ES

Tel: 020 7882 7250  
Email: Sponsorsrep@bartshealth.nhs.uk

Dear Dr Hart,

**Protocol: United Kingdom adult Idiopathic Thrombocytopenic Purpura (ITP) registry: An investigation of disease progression, treatment effectiveness, and co-morbid conditions. UKITP**

**ReDA Ref: 005148 QM**  
**REC Ref: 07/H0718/57**

Following review of the amendment dated **12 June 2017** for the above referenced study, Barts Health NHS Trust can confirm that this amendment does not affect current governance approval. The following documents were received:

Type	Version	Date
Covering letter on headed paper [signed Dr Provan		28 April 2017
Notice of Substantial Amendment (non-CTIMP) [signed by sponsor]	Substantial Amendment 5	12 June 2017
Other [Declaration signed Dr Hart]		27 April 2017
Other [Certificate Good Clinical Practice		13 July 2016
Summary CV for Chief Investigator (CI) [Dr Hart		01 January 2017

Barts Health NHS Trust can therefore continue to participate in the study and our files have been updated to reflect the changes. Please ensure that all updated patient documents contain appropriate logos, local information and contacts.

We wish you all the best with your research, and if you need any help or assistance during its course, please do not hesitate to contact the Office.

Yours sincerely



Dr. Sally Burtles  
Director of Research Services & Business Development

Copy to: Sponsor Organisation  
CRN (if applicable)

